tocilizumab · Medicine question

What type of cytokine release syndrome is RoActemra (tocilizumab) indicated to treat, and in which age groups?

Name: What type of cytokine release syndrome is RoActemra (tocilizumab) indicated to treat, and in which age groups?
Published: 2026-11-08T02:04:19.426Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

RoActemra (tocilizumab) is indicated to treat chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and paediatric patients aged 2 years and older.

Sources for this answer

RoActemra 20mg/ml Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 37Document updated 19 March 2026

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about tocilizumab